ContraVir Pharma (CTRV) Begins Enrollment in CMX157 Phase 2a Dose-Escalation Study
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
ContraVir Pharma (CTRV) Climbs to Session High, Shares Up 17%
October 17, 2016 10:20 AM EDTContraVir Pharma (NASDAQ: CTRV) Climbs to Session High, Shares Up 17%
... MoreMaxim Keeps ContraVir Pharma (CTRV) at 'Buy' as CMX157 Progresses into Phase 2a for HBV
October 17, 2016 8:53 AM EDTMaxim affirms ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) with a Buy rating and $4 price target after the company announced that following a positive recommendation from an independent Data Safety Monitoring Board (DSMB), the company has begun enrolling the next dosing group in its head-to-head Phase 2a... More
Maxim Positive on ContraVir Pharma (CTRV) Following CMX157 Phase 2a Update
October 13, 2016 7:30 AM EDTMaxim affirms ContraVir Pharmaceuticals (Nasdaq: CTRV) at Buy with a price target of $4 after the company reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study.
Maxim noted:
More... MoreContraVir Pharma (CTRV) Says CMX157 Demonstrates Significant Viral Load Reduction in Phase 2a Study in Hepatitis B
October 13, 2016 6:39 AM EDTContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead's Viread®) in chronically infected hepatitis B (HBV) patients.
Patients successfully completed both 5 mg and 10 mg cohorts, and interim data reported below are from 10 HBV-infected patients who completed 14... More